Biohit Oyj - Company Announcement

FINANCIAL TARGETS OF BIOHIT OYJ

Biohit has determined its financial targets for both the current year and
medium-term as follows: 

The short-term target is to reach a profitable growth of more than 10 per cent
annually, and to raise the total operating result to approximately 5 per cent
of total net sales in 2011. 

The medium-term target is to grow total net sales to EUR 70 million in 2013.

The net sales target for the liquid handling business for 2013 is EUR 50
million, representing an annual growth of more than 10 per cent. Our objective
is to be the leading electronic pipette manufacturer in all market areas
globally. We particularly seek to gain a stronger position in the North
American, South American, and Asian markets. To reach these goals, we must
ensure the following: 

  -- Research and development and business development must be based on
     customer-oriented, innovative solutions serving customers' real needs.
  -- The product range must be renewed and expanded more quickly and
     cost-efficiently.
  -- OEM and service businesses will account for a larger proportion of net
     sales.

Strong sales growth is sought particularly in the diagnostics business. The net
sales target for 2013 is EUR 20 million, which means an annual growth of more
than 80 per cent. Key means to achieving this target include: 

  -- Emphasis in the core business on key products: the GastroPanel and Acetium
     products.
  -- More resources allocated to product group commercialisation.
  -- The current product range will be developed.
  -- Effective use of the company's existing sales and marketing network to find
     the right local partners.

Board of Directors of Biohit Oyj



Further information:

Jussi Heiniö, President and CEO
Tel: +358 (0) 9 773 861
jussi.heinio@biohit.com

Distribution:

NASDAQ OMX Helsinki Oy
Central storage facility (www.oam.fi)
Press
www.biohit.com

About Biohit Oyj:

Biohit Oyj is a globally operating Finnish biotechnology company that was
established in 1988. The company's mission is to improve human health and
quality of life. The company follows a goal-directed and long-term innovation
and patenting strategy. 

Biohit works with scientific communities to produce new technologies, products
and services based on research results and innovations that can be used to
develop safe and cost-effective liquid handling solutions for laboratory work
as well as diagnostic tests for the early detection and prevention of diseases
of the gastrointestinal tract. 

Biohit has two business segments: liquid handling and diagnostics. Liquid
handling products include electronic and mechanical pipettes, disposable tips
as well as pipette maintenance and calibration services for research
institutions, healthcare and industrial laboratories. 

The diagnostics business comprises products and analysis systems for the early
diagnosis and prevention of gastrointestinal diseases, such as the blood-sample
based GastroPanel examinations for the diagnosis of stomach illnesses and
associated risks, quick tests for the diagnosis of lactose intolerance and H.
pylori infection in connection with gastroscopy, and the ColonView examination
for the early detection of intestinal bleeding that indicates a risk of
colorectal cancer. Acetium reduces the amount of carcinogenic acetaldehyde in
an anacidic stomach. 

The Biohit Group employs around 400 people. The company is headquartered in
Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia,
India, China, Japan and the USA. The company also has a representative office
in Singapore. Biohit's products are also sold through about 200 distributors in
70 countries. 

Since 1999, Biohit's Series B share has been quoted on NASDAQ OMX Helsinki in
the Small cap/Healthcare group and is traded under the code BIOBV. 

Read more at www.biohit.com